Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function

This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with mild and moderate hepatic impairment compared to participants with normal hepatic function.

NCT Number	NCT07551557
Lead Sponsor	Jiangsu vcare pharmaceutical technology co., LTD
Conditions	Hepatic Impairment and Healthy Female
Enrollment	24 participants
Start Date	2026-04-29
Primary Completion	2026-10-30 (estimated)
Study Completion	2026-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-07